The Neuro (Montreal Neurological Institute and Hospital) will lead an open science partnership to develop precision drugs for amyotrophic lateral sclerosis (ALS) and Parkinson’s disease (PD).
When prescribed the anticoagulant drug warfarin, many patients are told to limit foods rich in vitamin K, such as green vegetables. The results of a new clinical trial call that advice into question and suggest patients on warfarin actually benefit from increasing their vitamin K intake—as long as they keep their intake levels consistent.
AMP has revised its official position for all consumer genomic testing. Based on a recent assessment of the current market landscape and privacy best practices, the latest position statement features an expanded list of conditions that must be met before AMP can support a clinically-meaningful test.
A clinical trial that followed more than 9,900 people in 24 countries has found that the drug dulaglutide reduced cardiovascular events and kidney problems in middle-aged and older people with Type 2 diabetes.
During more than five years of follow-up, cardiovascular events like heart attacks and strokes were reduced by 12% in people taking dulaglutide compared to people taking a placebo. This effect was seen in both men and women with or without previous cardiovascular disease.
Results of a Phase II clinical trial conducted at The University of Texas MD Anderson Cancer Center revealed that combination targeted therapy, consisting of rituximab, lenalidomide and ibrutinib (RLI), had an 84.6 percent overall response rate (ORR) and 38.5 percent complete response rate (CRR) when given prior to any chemotherapy for newly diagnosed patients with a specific type of diffuse large b-cell lymphoma (DLBCL).
Results of a phase 3 clinical trial by researchers at UCLA’s Jonsson Comprehensive Cancer Center found that women with HER2-positive breast cancer had significantly better response rates, but more severe side effects, when they were treated with traditional neoadjuvant chemotherapy along with dual HER2-targeted blockade, compared to a more novel approach using HER2-targeted chemotherapy plus HER2-targeted blockade.
There are no approved treatment options for patients with advanced bladder cancer after standard chemotherapy and immune treatments, but the results of a phase II clinical trial led by Yale Cancer Center and Smilow Cancer Hospital researchers demonstrates an effective treatment for this deadly disease.
Georgetown University Medical Center announces the launch of the only known therapeutic (disease modifying) clinical trial for Lewy body dementia, a neurological disorder that affects a million people in the United States for which there are no approved medications that modify the disease.
Neoadjuvant, or pre-surgical, treatment with nivolumab plus ipilimumab resulted in an overall major pathologic response (MPR) rate of 33 percent of treated patients with early-stage, resectable non-small cell lung cancers, meaning these patients had less than or equal to 10 percent viable tumor remaining at surgery. With these results, the combination immunotherapy met the pre-specified trial efficacy endpoint of the phase II NEOSTAR trial conducted by researchers at The University of Texas MD Anderson Cancer Center.
Today the New England Journal of Medicine published the first results of a phase III international clinical study called TITAN (National Clinical Trials Number 02489318), which evaluated the effectiveness and safety of a new drug, apalutamide, to treat advanced prostate cancers. This publication accompanies a presentation today that outlines the study results at the American Society for Clinical Oncology (ASCO). Researchers found that treatment with apalutamide significantly improved overall survival, with a 33% reduction in risk of death compared to standard-of-care therapy. Additionally, this study showed apalutamide significantly delayed disease progression and increased the amount of time until a patient has to receive chemotherapy.
Studies to be presented at the ASCO meeting are co-authored by research oncologists Eric Whitman, MD; Missak Haigentz, MD; and Angela Alistar, MD. Their ASCO studies include: two separate studies looking at TILS therapy and Keytruda for advanced melanoma; immunotherapy for metastatic head and neck cancer; treatment for recurrent Epstein-Barr virus (EBV)-positive nasopharyngeal carcinoma; and a combination of CPI-613 -- a new type of medication, pioneered by Dr. Alistar, known as an altered energy metabolism drug -- with 5-FU in treating metastatic colorectal cancer.
UNMC is the only institution in the central plains region participating in the research. Globally, 880 patients will be enrolled at 130 sites in 20 countries. Researchers will follow patients for up to five years.
Clinical Research Pathways, a non-profit that advocates for increasing diversity in clinical research and expanding access to experimental drugs, biologics and medical devices, has added a new member to its board of directors.
Findings from Rutgers Cancer Institute of New Jersey focused on immunotherapy will be featured at the 2019 American Society of Clinical Oncology Annual Meeting being held in Chicago tomorrow through Tuesday.
Cancer patients previously excluded and underrepresented in immunotherapy clinical trials, such as African Americans and patients with HIV or viral hepatitis, actually benefit at the same rate as patients tested in the clinical trials, according to a Georgetown-led study to be presented at the 2019 ASCO Annual Meeting in Chicago.
A survey conducted by Georgetown investigators found a significant knowledge and practice gap among community oncologists in the understanding and usage of genetic testing in determining patients' treatment plans and potential clinical trial outcomes.
Something as simple as a phone call could be a way to alert health care providers and caregivers that an elderly person suffering from dementia may be spiraling down to dangerous self-neglect, according to researchers at The University of Texas Health Science Center at Houston (UTHealth).
Fred Hutchinson Cancer Research Center’s latest findings in immunotherapy, prevention of cancer-linked viruses, health care disparities and more will be showcased at the annual meeting of the American Society of Clinical Oncology. The conference, “Caring for Every Patient, Learning from Every Patient,” will be held May 31-June 4 in Chicago. See highlights below.
Today, the Journal of the American College of Radiology (JACR®) published a report detailing real-world artificial intelligence (AI) challenges and summarizing the priorities for translational research in AI for medical imaging to help accelerate the safe and effective use of AI in clinical practice.
The Cancer Research Institute announced today a series of public education and awareness offerings during its seventh annual Cancer Immunotherapy Month™ in June.
A new method of assessing the actions of medicines by matching them to their unique protein receptors has the potential to greatly accelerate drug development and diminish the number of drug trials that fail during clinical trials.
Case Comprehensive Cancer Center has been selected, once again, as a Lead Academic Participating Site by the National Cancer Institute. The renewal comes with a six-year, $8.9 million grant that will enable the center to provide patients with additional access to clinical trials through the National Clinical Trials Network. In this renewal, NCI is committed to improving the resources provided for each patient to cover research costs at levels linked to the complexity of the clinical trial.
As many as 90 percent of individuals who have a parent with Huntington’s disease (HD) choose not to take a gene test that reveals if they will also develop the fatal disorder — and a new study details the reasons why. Understanding the “why” matters as new clinical trials testing therapies for people who haven’t yet developed symptoms of Huntington disease requires participants to be tested for the HD gene to be included in the trials.
A new clinical trial at The Ohio State University Wexner Medical Center and two other sites is testing an innovative procedure that may provide hope in the fight against Alzheimer’s disease.
The non-invasive procedure uses low-intensity focused ultrasound to open the blood-brain barrier.
The University of Illinois at Chicago will lead a $14.6 million, multi-center research project to determine which of two drugs — azithromycin, an antibiotic, or roflumilast, an anti-inflammatory medication — is the most effective at treating chronic obstructive pulmonary disease, which is also known as COPD.
Participants in a phase I/II clinical trial of a new enzyme-based treatment for severe dry eye disease experienced reduced signs of disease and discomfort, according to a paper in Translational Vision Science and Technology.The trial compared eye drops containing a biosynthetic form of an enzyme called DNase with eye drops without the enzyme.
A new clinical trial finds transcatheter aortic valve replacement (TAVR) to be equivalent or potentially preferable to surgical aortic valve replacement (SAVR) for low risk patients.
A new study shows that a potential treatment for ischemia- reperfusion injury is safe for humans. Building upon three decades of preclinical animal studies, this NIH-funded trial demonstrated, for the first time, the safety of Regadenoson (an adenosine 2A receptor agonist) in human lung transplant patients.
The American Association for Thoracic Surgery 99th Annual Meeting takes place at the Metro Toronto Convention Center, Toronto, Canada, May 4 - 7, 2019.
Scientists at Seattle Children’s Research Institute are paving the way to use gene-edited B cells – a type of white blood cell in the immune system – to treat a wide range of potential diseases that affect children, including hemophilia and other protein deficiency disorders, autoimmune diseases, and infectious diseases.
Taking a pharmaceutical formulation of cannabidiol, a cannabis-based medicine, cut seizures nearly in half for children with a rare and severe type of epilepsy called Dravet syndrome, according to a phase 3 study released today that will be presented at the American Academy of Neurology’s 71st Annual Meeting in Philadelphia, May 4 to 10, 2019. Dravet syndrome, which starts in infancy, can lead to intellectual disability and frequent, prolonged seizures. Cannabidiol is derived from marijuana that does not include the psychoactive part of the plant that creates a “high.”
Ablacon, Inc. (www.ablacon.com), a Wheat Ridge, CO-based company developing an advanced mapping system to guide the treatment of atrial fibrillation (AFib)
Scientists at the UCLA Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research have been awarded a $4.6 million grant from the California Institute for Regenerative Medicine – also known as CIRM – to support a phase I clinical trial of a novel treatment for advanced sarcomas and other cancers with a specific tumor marker called NY-ESO-1.
A USC Norris study aims to increase clinical trial enrollment among low-income patients and racial and ethnic minorities by offering financial assistance for out-of-pocket costs associated with the trial. Because patients from low-income and racial minorities enroll in clinical trials at much lower rates, researchers are not capturing accurate data about personalized cancer care within these groups.
Penn Nursing’s Rosemary Polomano, PhD, RN, FAAN, Associate Dean for Practice Professor of Pain Practice, and M. Kit Delgado, MD, MS, Assistant Professor of Emergency Medicine and Epidemiology at Penn’s Perleman School of Medicine, have been appointed members of the National Academies of Sciences, Engineering, and Medicine’s (the Academies) Committee on Evidence-based Clinical Practice Guidelines to Prescribing Opioids for Acute Pain.
An investigational drug that may block harmful antibodies from passing through the placenta of an expectant mother to the fetus is the focus of a new clinical trial led by Kenneth Moise, MD, a maternal-fetal medicine specialist at UTHealth.
Researchers at University of California San Diego School of Medicine found using blood thinners in patients with worsening heart failure, coronary artery disease and irregular heart rhythms was associated with a reduced risk of thromboembolic events, such as stroke and heart attack.
University of California San Diego School of Medicine researchers found that treating patients with personalized precision medicine that combined therapies to target multiple alterations improved outcomes in patients with therapy resistant cancers.
• The Time to Reduce Mortality in ESRD (TiME) trial was a large pragmatic trial demonstration project designed to determine the benefits of hemodialysis sessions that are longer than many patients currently receive.
• The trial was conducted through a partnership between academic investigators and 2 large dialysis provider organizations using a highly centralized implementation approach.
• Although the trial accomplished most of its demonstration project objectives, uptake of the intervention was insufficient to determine whether longer sessions improve outcomes.
The University of Chicago will lead the NRG Oncology Statistics and Data Management Center, which is receiving six more years of funding from the National Cancer Institute.
New research suggests that the microbial communities associated with chronic wounds common in diabetic patients affect whether those wounds heal or lead to amputations.
Small children may one day avoid invasive, painful and often traumatic oesophageal tube-testing for gut damage and coeliac disease with a new method of simply blowing into a glass tube to provide effective diagnoses.
Research published in international journal Scientific Reports describes an exciting new breath test that could have global implications on how to detect gastrointestinal damage.
“Magic mouthwash,” an oral rinse containing diphenhydramine, lidocaine and antacids, significantly reduced pain from oral mucositis, mouth sores, in patients receiving radiation therapy for cancers of the head and neck when compared to plaecbo. These were the findings of a multi-institution, randomized, double-blind, placebo-controlled, phase III clinical trial, led by Robert Miller, M.D., an emeritus Mayo Clinic radiation oncologist. Dr. Miller and his colleagues published their findings on Tuesday, April 16, in JAMA.
Patient-reported outcomes (PROs) are an important target for efforts to improve healthcare – focusing on the most important problems and outcomes identified by patients themselves. A special supplement to Medical Care presents a toolkit of methods to help personalize care for patients with cancer using a 'PRO cision Medicine' approach. The journal is published in the Lippincott portfolio by Wolters Kluwer.